Loading…
Employees: 27,686
Size MedPlus Health Services (MEDPLUS.NS) is an India Consumer Staples company (Drugstore Chains) with a market value of $769M, the 684th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹604.60 on 6 Nov 2026.
Performance Over six months the shares fell 31.4%, against -1.2% for the median peer and 0.0% for the India market (cap-weighted) — 3rd lowest of 17 in its peer set.
Growth Revenue grew 20.6% over the last twelve months (peer median +5.6%); the operating margin is 4.2% (peer median 4.5%).
Valuation It trades at 35.1× forward earnings against a peer median of 13.7× (most expensive of 10).
Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.1 points below its cost of capital (9.5% WACC).
Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹75.9B | ₹68.9B | ₹61.4B | ₹56.2B | ₹45.6B |
| Revenue growth | — | +12% | +9% | +23% | — |
| Gross profit | ₹6.64B | ₹6.27B | ₹5.08B | ₹3.74B | ₹2.67B |
| EBITDA | ₹6.31B | ₹6.10B | ₹4.90B | ₹3.56B | ₹2.68B |
| Net income | ₹2.11B | ₹2.20B | ₹1.50B | ₹655M | ₹498M |
| Free cash flow | n/a | ₹4.04B | ₹4.95B | ₹729M | -₹582M |
| Capital expenditure | n/a | ₹1.23B | ₹594M | ₹844M | ₹1.69B |
| Total debt | ₹15.5B | ₹14.2B | ₹11.2B | ₹10.1B | ₹9.00B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MEDPLUS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.6% | +2.0% | 6th lowest of 17 |
| 6-month return | -31.4% | -1.2% | 3rd lowest of 17 |
| Distance from 52-week high | -40.9% | -28.2% | 5th lowest of 17 |
| Revenue growth (TTM) | +20.6% | +5.6% | 3rd highest of 17 |
| Operating margin | 4.2% | 4.5% | 8th lowest of 17 |
| Forward P/E | 35.1× | 13.7× | most expensive of 10 |
| Growth the price implies (Req g, 7 yrs) | 18.5% | -6.3% | 2nd most demanding of 15 |
| Growth delivered (Del g) | +17.6% | +8.9% | 2nd highest of 15 |
| Hurdle (Req g minus delivered) | +0.9 pp | -16.7 pp | 3rd most demanding of 15 |
| ROIC minus cost of capital | -2.1 pp | +2.7 pp | 4th lowest of 17 |
| EV / EBITDA | 13.4× | 6.4× | 3rd most expensive of 8 |
| Net debt / EBITDA | 1.9× | -0.4× | 2nd most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| MedPlus Health Services MEDPLUS.NS | India | $769M | -31% | +21% | 4% | 35.1× | 18.5% | +17.6% |
| Genky DrugStores 9267.T | Japan | $723M | +3% | +8% | 5% | 13.7× | n/a | n/a |
| Anhui Huaren Health Pharmaceutical 301408.SZ | China | $829M | -35% | +15% | 8% | n/a | -6.0% | +23.3% |
| Shu Yu Civilian Pharmacy 301017.SZ | China | $872M | +9% | +9% | 2% | n/a | 4.0% | +17.4% |
| Beijing Konruns Pharmaceutical 603590.SS | China | $617M | -28% | +4% | 20% | 21.0× | 11.6% | +2.7% |
| Cawachi 2664.T | Japan | $577M | +37% | -1% | 2% | n/a | -5.8% | 0.0% |
| Qol 3034.T | Japan | $567M | +38% | +7% | 6% | 11.3× | -16.2% | +12.4% |
| Luyan Pharma 002788.SZ | China | $555M | -30% | +3% | 3% | n/a | 0.1% | +6.5% |
| Yixintang Pharmaceutical 002727.SZ | China | $1.18B | +6% | -2% | 3% | 16.9× | -15.9% | +6.5% |
| Ain 9627.T | Japan | $1.23B | -2% | +42% | 4% | 13.4× | -6.5% | +16.9% |
| Create SD 3148.T | Japan | $1.30B | -2% | +9% | 5% | n/a | -11.5% | +8.0% |
| Landfar Bio-medicine 000504.SZ | China | $395M | -16% | +497% | -2% | n/a | n/a | n/a |
| LBX Pharmacy Chain Joint Stock 603883.SS | China | $1.69B | +7% | +3% | 5% | 16.3× | -10.9% | +9.7% |
| Shanghai No. 1 Pharmacy 600833.SS | China | $314M | -24% | +1% | -1% | n/a | 20.4% | +6.1% |
| JZJ Chain Drugstore Corporation 605266.SS | China | $307M | -34% | -5% | 0% | 6.5× | -9.6% | +14.8% |
| Guardian Pharmacy Services GRDN | United States | $2.68B | +17% | +10% | 6% | 30.6× | 4.1% | +16.8% |
| Sundrug 9989.T | Japan | $2.77B | -1% | +4% | 5% | 13.3× | -8.0% | +5.8% |